9087-70-1
Product Name:
Aprotinin
Formula:
C284H432N84O78R2S7
Synonyms:
Aprotinin from bovine lung;Trasylol;Trypsin inhibitor (basic);trypsin inhibitor, pancreas type (bpti);trypsin-kallikrein inhibitor
Inquiry
CHEMICAL AND PHYSICAL PROPERTIES
| Physical Description | White powder; [Sigma-Aldrich MSDS] |
|---|---|
| Color/Form | Clear, colorless |
| Melting Point | >100 °C |
| Other Experimental Properties | Isoelectric point pH 10.5. Stable in neutral or acidic media at high temp. Irreversible changes in molecular structure occur in strongly alkaline media (pH >12). Partially and reversibly denatured on treatment with 8M urea. May be kept at room temp in physiological saline soln for >1 yr without detrimental effects. |
| Chemical Classes | Other Uses -> Biochemical Research |
SAFETY INFORMATION
| Signal word | Warning |
|---|---|
| Pictogram(s) |
 Exclamation Mark Irritant GHS07 |
| GHS Hazard Statements |
H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
| Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P271:Use only outdoors or in a well-ventilated area. P280:Wear protective gloves/protective clothing/eye protection/face protection. |
COMPUTED DESCRIPTORS
| Molecular Weight | 6511 g/mol |
|---|---|
| XLogP3 | -25.4 |
| Hydrogen Bond Donor Count | 93 |
| Hydrogen Bond Acceptor Count | 97 |
| Rotatable Bond Count | 111 |
| Exact Mass | 6510.0514478 g/mol |
| Monoisotopic Mass | 6507.0413833 g/mol |
| Topological Polar Surface Area | 2820 Ų |
| Heavy Atom Count | 454 |
| Formal Charge | 0 |
| Complexity | 16700 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 57 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently-Bonded Unit Count | 1 |
| Compound Is Canonicalized | Yes |
PRODUCT INTRODUCTION
description
Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery. Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death. The substance is consequently made available only for very restricted research use.